Suggested remit: To appraise the clinical and cost effectiveness of risankizumab within its marketing authorisation for treating active psoriatic arthritis.
 
Status In progress
Process STA 2018
ID number 1399

Provisional Schedule

Committee meeting: 1 04 August 2022
Expected publication 19 October 2022

Project Team

Project lead Louise Jafferally

Email enquiries

Consultees

Companies sponsors AbbVie (risankizumab)
Others Department of Health and Social Care
  NHS East and North Hertfordshire CCG
  NHS England
  NHS Derby and Derbyshire CCG
  Welsh Government
Patient carer groups Action on Pain
  Arthritis Action
  Arthritis and Musculoskeletal Alliance
  National Rheumatoid Athritis Society
  Pain Concern
  Pain UK
  Psoriasis and Psoriatic Arthritis Alliance
  Psoriasis Association
  Psoriasis Help Organisation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Versus Arthritis
Professional groups British Association of Dermatologists
  British Dermatological Nursing Group
  British Geriatrics Society
  British Institute of Musculoskeletal Medicine
  British Myology Society
  British Orthopaedic Association
  British Skin Foundation
  British Society for Rheumatology
  British Society of Rehabilitation Medicine
  Health Lumen
  Physiotherapy Pain Association
  Primary Care Dermatology Society
  Primary Care Rheumatology Society
  Rheumatoid Arthritis Surgical Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for Endocrinology
  UK Clinical Pharmacy Association

Commentators

Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies AbbVie (adalimumab, upadacitinib)
  Accord Healthcare (methotrexate)
  ADVANZ Pharma (methotrexate)
  Amgen (adalimumab, apremilast)
  Biogen Biosimilars (adalimumab, etanercept, infliximab)
  Celltrion Healthcare (adalimumab, infliximab)
  Cipla EU (methotrexate)
  Eli Lilly and Company (ixekizumab)
  Fresenius Kabi (adalimumab)
  Hospira (methotrexate)
  Janssen-Cilag (guselkumab, ustekinumab)
  Medac (methotrexate)
  Merck Sharp & Dohme (golimumab, infliximab)
  Morningside Healthcare (methotrexate)
  Nordic Pharma (methotrexate)
  Novartis Pharmaceuticals (secukinumab)
  Orion Pharma (methotrexate)
  Pfizer (etanercept, infliximab, methotrexate, tofacitinib)
  Rosemont Pharmaceuticals (methotrexate)
  Sandoz (adalimumab, etanercept, infliximab, methotrexate)
  Therakind (methotrexate)
  UCB Pharma (certolizumab pegol)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Bone Research Society
  British Epidermo-Epidemiology Society
  British Psoriatic Arthritis ConsorTium
  Centre of Evidence-based Dermatology, University of Nottingham
  Chronic Pain Policy Coalition
  Cochrane Musculoskeletal Group
  Cochrane Skin Group
  Cochrane UK
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research
  Orthopaedic Research UK
  Pain Relief Foundation
  Skin Treatment and Research Trust

Timeline

Key events during the development of the guidance:

Date Update
23 November 2021 In progress. Invitation to participate issued.
23 November 2021 Invitation to participate
02 March 2021 - 30 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance